Evaluating the Journey of Amanitin ADC Development Contextualised with HDP-101 Phase I/ II Clinical Data to Lay the Path for ADC Payload Differentiation
- Laying out amanitin-based ADC as promising approach to overcoming drug resistance through differentiated payload mechanism of action
- Showcasing phase I/II dose escalation data of HDP-101: clinical performance and excellent safety and tolerability
- Explaining lessons learned across opportunities and hurdles of bringing a novel ADC payload to the clinic